Keyphrases
Metastatic Castration-resistant Prostate Cancer (mCRPC)
100%
Chemotherapy
100%
Enzalutamide
100%
Abiraterone Acetate
100%
Prostate-specific Antigen Response
100%
Abiraterone
55%
Prostate Cancer Patients
33%
Docetaxel
33%
Post-chemotherapy
22%
Prostate-specific Antigen
22%
Mann-Whitney U Test
11%
Linear Regression Model
11%
Succeeding
11%
Randomized Trial
11%
Exact Test
11%
Cabazitaxel
11%
Overall Survival
11%
Prior Cancer
11%
Cancer Treatment
11%
Median Overall Survival
11%
Pharmacology, Toxicology and Pharmaceutical Science
Castration Resistant Prostate Cancer
100%
Prostate Specific Antigen
100%
Enzalutamide
100%
Abiraterone Acetate
100%
Chemotherapy
100%
Abiraterone
45%
Docetaxel
27%
Overall Survival
18%
Malignant Neoplasm
9%
Prospective Study
9%
Cabazitaxel
9%
Neuroscience
Abiraterone Acetate
100%
Prostate Specific Antigen
100%
Enzalutamide
100%
Abiraterone
45%
Prostate
36%
Docetaxel
27%
Cabazitaxel
9%